持田製薬(株)の貸借残高情報
主市場 | 業種 | 証券コード/EDINET | 英名称 |
---|
東証PRM | 医薬品 | 4534/E00947 | - |
公表日 | 公表 | 貸付残高 | 前週比 | 新規貸付成約高 | 前週比 | 借入残高 | 前週比 | 新規借入成約高 | 前週比 |
---|
2019/07/05 | 日証協 | 219,358株 | +15.48% | 41,700株 | -25.01% | 208,480株 | +7.3% | 33,284株 | -36.47% |
2019/06/28 | 日証協 | 189,958株 | +21.69% | 55,604株 | +203.85% | 194,296株 | +16.97% | 52,390株 | +36.43% |
2019/06/21 | 日証協 | 156,094株 | -4.06% | 18,300株 | -24.69% | 166,110株 | -1.3% | 38,400株 | -43.36% |
2019/06/14 | 日証協 | 162,694株 | +19.11% | 24,300株 | -63.62% | 168,297株 | +15.75% | 67,800株 | -4.78% |
2019/06/07 | 日証協 | 136,594株 | +2.92% | 66,800株 | +851.03% | 145,397株 | -0.9% | 71,200株 | +88.41% |
2019/05/31 | 日証協 | 132,718株 | -21.72% | 7,024株 | -91.78% | 146,720株 | -9.46% | 37,790株 | -67.34% |
2019/05/24 | 日証協 | 169,544株 | -27.4% | 85,424株 | -12.38% | 162,048株 | +2.44% | 115,700株 | +207.42% |
2019/05/17 | 日証協 | 233,538株 | +20.04% | 97,494株 | +88.02% | 158,186株 | -3.36% | 37,636株 | +44.74% |
2019/05/10 | 日証協 | 194,548株 | -1.7% | 51,854株 | -43.04% | 163,686株 | -5.76% | 26,002株 | +30.01% |
2019/04/26 | 日証協 | 197,908株 | +12.3% | 91,028株 | +25.66% | 173,686株 | -12.18% | 20,000株 | -65.4% |
2019/04/19 | 日証協 | 176,232株 | +3.89% | 72,440株 | -15.52% | 197,784株 | -11.82% | 57,802株 | -29.77% |
2019/04/12 | 日証協 | 169,634株 | -5.62% | 85,748株 | -69.12% | 224,284株 | -7.83% | 82,302株 | -63.25% |
2019/04/05 | 日証協 | 179,739株 | +213.52% | 277,714株 | +90.79% | 243,334株 | +91.24% | 223,927株 | +18.77% |
2019/03/29 | 日証協 | 57,330株 | -19.41% | 145,558株 | +29.24% | 127,243株 | +4.03% | 188,544株 | +104.78% |
2019/03/22 | 日証協 | 71,139株 | -20.47% | 112,626株 | -24.28% | 122,318株 | -18% | 92,073株 | +32.01% |
2019/03/15 | 日証協 | 89,451株 | +42.98% | 148,741株 | +112.31% | 149,162株 | -0.17% | 69,745株 | +30.6% |
2019/03/08 | 日証協 | 62,560株 | -7.03% | 70,060株 | -4.17% | 149,414株 | -12.47% | 53,404株 | -26.99% |
2019/03/01 | 日証協 | 67,293株 | +19.4% | 73,107株 | +41.91% | 170,694株 | +23.16% | 73,143株 | +43.58% |
2019/02/22 | 日証協 | 56,360株 | -28.46% | 51,517株 | +74.1% | 138,594株 | -1.72% | 50,941株 | +50.61% |
※株式分割は考慮していませんのでご注意ください。
Page Top